| 2.94 -0.03 (-1.01%) | 11-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.14 | 1-year : | 4.84 |
| Resists | First : | 3.54 | Second : | 4.14 |
| Pivot price | 1.25  |
|||
| Supports | First : | 1.59 | Second : | 0.39 |
| MAs | MA(5) : | 2.56 |
MA(20) : | 1.06 |
| MA(100) : | 0.51 |
MA(250) : | 0.88 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 75.6 |
D(3) : | 72.2 |
| RSI | RSI(14): 79.1 |
|||
| 52-week | High : | 3.57 | Low : | 0.22 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CYPH ] has closed below upper band by 9.6%. Bollinger Bands are 1082% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.38 - 3.39 | 3.39 - 3.41 |
| Low: | 2.66 - 2.68 | 2.68 - 2.7 |
| Close: | 2.91 - 2.94 | 2.94 - 2.97 |
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025. The company was incorporated in 2011 and is based in Cambridge, Massachusetts.
Wed, 19 Nov 2025
CYPH Stock Price and Chart — NASDAQ:CYPH - TradingView
Wed, 19 Nov 2025
Cypherpunk (CYPH) Stock: Doubles Down on Zcash With $18M Purchase as Privacy Coin Surges 140% - parameter.io
Wed, 19 Nov 2025
Zcash (ZEC) News: Winklevoss' DAT Cypherpunk (CYPH) Buys $18M Tokens - CoinDesk
Tue, 18 Nov 2025
Cypherpunk Technologies (CYPH) Expands ZEC Holdings with New Pur - GuruFocus
Tue, 18 Nov 2025
Cypherpunk Purchases Additional $18 Million of ZEC, Bringing Total Network Percentage to 1.43% - PR Newswire
Mon, 17 Nov 2025
Cypherpunk Technologies Inc. purchases another $18 million worth of ZEC, bringing its total holdings to 1.43% of the network supply. - Bitget
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 57 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 11.9 (%) |
| Held by Institutions | 28.6 (%) |
| Shares Short | 2,910 (K) |
| Shares Short P.Month | 943 (K) |
| EPS | -1.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.05 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -77.8 % |
| Return on Equity (ttm) | -196.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.84 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -53 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -1.87 |
| PEG Ratio | 0 |
| Price to Book value | 49 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|